ADPT Insider Trading

Insider Ownership Percentage: 6.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,041,858.67

Adaptive Biotechnologies Insider Trading History Chart

This chart shows the insider buying and selling history at Adaptive Biotechnologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$6M-$4M-$2M$0$2M$4M$6MTotal Insider BuyingTotal Insider Selling

Adaptive Biotechnologies Share Price & Price History

Current Price: $7.94
Price Change: Price Increase of +0.22 (2.85%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for ADPT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$7.94Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Adaptive Biotechnologies (NASDAQ:ADPT)

99.17% of Adaptive Biotechnologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ADPT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.09Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More on Adaptive Biotechnologies

Today's Range

Now: $7.94
Low: $7.38
High: $8.30

50 Day Range

MA: $7.91
Low: $6.67
High: $8.66

52 Week Range

Now: $7.94
Low: $2.28
High: $9.01

Volume

4,142,561 shs

Average Volume

1,519,909 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Who are the company insiders with the largest holdings of Adaptive Biotechnologies?

Adaptive Biotechnologies' top insider shareholders include:
  1. Chad M Robins (CEO)
  2. Harlan S Robins (Insider)
  3. Julie Rubinstein (COO)
  4. Tycho Peterson (CFO)
  5. Julie Rubinstein (President)
  6. Francis Lo (Insider)
  7. Kyle Piskel (CFO)
  8. Nitin Sood (Insider)
  9. Peter M Neupert (Director)
  10. Stacy L Taylor (SVP)
  11. Kyle Piskel (Insider)
  12. Robert Hershberg (Director)
  13. Michelle Renee Griffin (Director)
Learn More about top insider investors at Adaptive Biotechnologies.

Who are the major institutional investors of Adaptive Biotechnologies?

Adaptive Biotechnologies' top institutional investors include:
  1. Rhumbline Advisers — 0.13%
  2. GAMMA Investing LLC — 0.07%
  3. Alpha Wealth Funds LLC — 0.03%
Learn More about top institutional investors of Adaptive Biotechnologies stock.

Which major investors are buying Adaptive Biotechnologies stock?

Within the last quarter, ADPT stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Alpha Wealth Funds LLC
  3. Rhumbline Advisers